Prolia®
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Glucocorticoid-induced Osteoporosis
Conditions
Glucocorticoid-induced Osteoporosis
Trial Timeline
May 24, 2025 → May 24, 2027
NCT ID
NCT06588153About Prolia®
Prolia® is a approved stage product being developed by Amgen for Glucocorticoid-induced Osteoporosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06588153. Target conditions include Glucocorticoid-induced Osteoporosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06588153 | Approved | Recruiting |
Competing Products
1 competing product in Glucocorticoid-induced Osteoporosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab + Placebo for risendronate + Risendronate + Placebo for denosumab | Amgen | Phase 3 | 76 |